The Experts below are selected from a list of 31002 Experts worldwide ranked by ideXlab platform
Peter Kolominsky-rabas - One of the best experts on this subject based on the ideXlab platform.
-
Cost-of-Illness studies in heart failure: a systematic review 2004–2016
BMC cardiovascular disorders, 2018Co-Authors: Wladimir Lesyuk, Christine Kriza, Peter Kolominsky-rabasAbstract:Heart failure is a major and growing medical and economic problem worldwide as 1–2% of the healthcare budget are spent for heart failure. The prevalence of heart failure has increased over the past decades and it is expected that there will be further raise due to the higher proportion of elderly in the western societies. In this context Cost-of-Illness studies can significantly contribute to a better understanding of the drivers and problems which lead to the increasing Costs in heart failure. The aim of this study was to perform a systematic review of published Cost-of-Illness studies related to heart failure to highlight the increasing Cost impact of heart failure. A systematic review was conducted from 2004 to 2016 to identify Cost-of-Illness studies related to heart failure, searching PubMed (Medline), Cochrane, Science Direct (Embase), Scopus and CRD York Database. of the total of 16 studies identified, 11 studies reported prevalence-based estimates, 2 studies focused on incidence-based data and 3 articles presented both types of Cost data. A large variation concerning Cost components and estimates can be noted. Only three studies estimated indirect Costs. Most of the included studies have shown that the Costs for hospital admission are the most expensive Cost element. Estimates for annual prevalence-based Costs for heart failure patients range from $868 for South Korea to $25,532 for Germany. The lifetime Costs for heart failure patients have been estimated to $126.819 per patient. Our review highlights the considerable and growing economic burden of heart failure on the health care systems. The Cost-of-Illness studies included in this review show large variations in methodology used and the Cost results vary consequently. High quality data from Cost-of-Illness studies with a robust methodology applied can inform policy makers about the major Cost drivers of heart failure and can be used as the basis of further economic evaluations.
-
Cost of Illness in Colorectal Cancer: An International Review
PharmacoEconomics, 2013Co-Authors: Christine Kriza, Martin Emmert, Philip Wahlster, Charlotte Niederländer, Peter Kolominsky-rabasAbstract:Objectives Given the current—and increasing—pressure to limit expenditure on health care provision in many countries, a better understanding of the Cost burden of colorectal cancer is needed. Cost-of-Illness studies and reviews thereof can be a useful tool for analysing and critically evaluating the Cost-related development of colorectal cancer, and they highlight important Cost drivers.
Ralph M. Trüeb - One of the best experts on this subject based on the ideXlab platform.
-
Estimation of Cost-of-Illness in patients with psoriasis in Switzerland.
Swiss Medical Weekly, 2010Co-Authors: Alexander A. Navarini, Emanuel Laffitte, Curdin Conrad, Paolo Piffaretti, Elisabeth Brock, Stephan Ruckdaeschel, Ralph M. TrüebAbstract:BACKGROUND: Evaluation of the current clinical treatment of psoriasis in Switzerland remains to be measured with the parameters Cost-of-Illness and quality of life. Objective: To obtain data on out-of-pocket expenses, Costs of outpatient/office-based care and inpatient care for psoriasis, and to extrapolate total Costs by state of severity to the entire Swiss population. METHODS: 1200 retrospective surveys were distributed to patient members of the Swiss Psoriasis and Vitiligo Society, and 400 surveys to office-/hospital-based Swiss dermatologists. The reference year for data collection was 2005. Patients were stratified into three subgroups according to severity of disease. Costs of inpatient care were measured by the amount of hospital days of psoriatic patients from the Swiss Federal Hospital Statistics. RESULTS: 383 patient questionnaires, and 170 cases documented by 57 dermatologists were analyzed. Out-of-pocket expenses/Costs for ambulatory care per patient and year ranged from CHF 600-1100 for mild psoriasis to CHF 2400-9900 for severe psoriasis. Including Costs for inpatient care of approximately CHF 60 million, the total annual Costs for psoriasis in Switzerland in 2004/5 amounted to approximately CHF 314-458 million. CONCLUSIONS: Moderate-to-severe psoriasis is associated with a significant impact on the quality of life and at least 4-fold higher Costs than mild psoriasis, indicating the need for efficient control of the disease. This Cost-of-Illness study provides specific health economic data for future healthcare decision making, particularly with the advent of new therapeutic agents for effective psoriasis control.
-
Estimation of Cost-of-Illness in patients with psoriasis in Switzerland.
Swiss medical weekly, 2010Co-Authors: Alexander A. Navarini, Emanuel Laffitte, Curdin Conrad, Paolo Piffaretti, Elisabeth Brock, Stephan Ruckdaeschel, Ralph M. TrüebAbstract:Evaluation of the current clinical treatment of psoriasis in Switzerland remains to be measured with the parameters Cost-of-Illness and quality of life. To obtain data on out-of-pocket expenses, Costs of outpatient/office-based care and inpatient care for psoriasis, and to extrapolate total Costs by state of severity to the entire Swiss population. 1200 retrospective surveys were distributed to patient members of the Swiss Psoriasis and Vitiligo Society, and 400 surveys to office-/hospital-based Swiss dermatologists. The reference year for data collection was 2005. Patients were stratified into three subgroups according to severity of disease. Costs of inpatient care were measured by the amount of hospital days of psoriatic patients from the Swiss Federal Hospital Statistics. 383 patient questionnaires, and 170 cases documented by 57 dermatologists were analyzed. Out-of-pocket expenses/Costs for ambulatory care per patient and year ranged from CHF 600-1100 for mild psoriasis to CHF 2400-9900 for severe psoriasis. Including Costs for inpatient care of approximately CHF 60 million, the total annual Costs for psoriasis in Switzerland in 2004/5 amounted to approximately CHF 314-458 million. Moderate-to-severe psoriasis is associated with a significant impact on the quality of life and at least 4-fold higher Costs than mild psoriasis, indicating the need for efficient control of the disease. This Cost-of-Illness study provides specific health economic data for future healthcare decision making, particularly with the advent of new therapeutic agents for effective psoriasis control.
Anders Norlund - One of the best experts on this subject based on the ideXlab platform.
-
Cost of Illness of Multiple Sclerosis - A Systematic Review.
PloS one, 2016Co-Authors: Olivia Ernstsson, Hanna Gyllensten, Kristina Alexanderson, Petter Tinghög, Emilie Friberg, Anders NorlundAbstract:Background Cost-of-Illness (COI) studies of Multiple Sclerosis (MS) are vital components for describing the economic burden of MS, and are frequently used in model studies of interventions of MS. We conducted a systematic review of studies estimating the COI of MS, to compare Costs between studies and examine Cost drivers, emphasizing generalizability and methodological choices.
Christine Kriza - One of the best experts on this subject based on the ideXlab platform.
-
Cost-of-Illness studies in heart failure: a systematic review 2004–2016
BMC cardiovascular disorders, 2018Co-Authors: Wladimir Lesyuk, Christine Kriza, Peter Kolominsky-rabasAbstract:Heart failure is a major and growing medical and economic problem worldwide as 1–2% of the healthcare budget are spent for heart failure. The prevalence of heart failure has increased over the past decades and it is expected that there will be further raise due to the higher proportion of elderly in the western societies. In this context Cost-of-Illness studies can significantly contribute to a better understanding of the drivers and problems which lead to the increasing Costs in heart failure. The aim of this study was to perform a systematic review of published Cost-of-Illness studies related to heart failure to highlight the increasing Cost impact of heart failure. A systematic review was conducted from 2004 to 2016 to identify Cost-of-Illness studies related to heart failure, searching PubMed (Medline), Cochrane, Science Direct (Embase), Scopus and CRD York Database. of the total of 16 studies identified, 11 studies reported prevalence-based estimates, 2 studies focused on incidence-based data and 3 articles presented both types of Cost data. A large variation concerning Cost components and estimates can be noted. Only three studies estimated indirect Costs. Most of the included studies have shown that the Costs for hospital admission are the most expensive Cost element. Estimates for annual prevalence-based Costs for heart failure patients range from $868 for South Korea to $25,532 for Germany. The lifetime Costs for heart failure patients have been estimated to $126.819 per patient. Our review highlights the considerable and growing economic burden of heart failure on the health care systems. The Cost-of-Illness studies included in this review show large variations in methodology used and the Cost results vary consequently. High quality data from Cost-of-Illness studies with a robust methodology applied can inform policy makers about the major Cost drivers of heart failure and can be used as the basis of further economic evaluations.
-
Cost of Illness studies in heart failure a systematic review 2004 2016
BMC Cardiovascular Disorders, 2018Co-Authors: Wladimir Lesyuk, Christine Kriza, P KolominskyrabasAbstract:Heart failure is a major and growing medical and economic problem worldwide as 1–2% of the healthcare budget are spent for heart failure. The prevalence of heart failure has increased over the past decades and it is expected that there will be further raise due to the higher proportion of elderly in the western societies. In this context Cost-of-Illness studies can significantly contribute to a better understanding of the drivers and problems which lead to the increasing Costs in heart failure. The aim of this study was to perform a systematic review of published Cost-of-Illness studies related to heart failure to highlight the increasing Cost impact of heart failure. A systematic review was conducted from 2004 to 2016 to identify Cost-of-Illness studies related to heart failure, searching PubMed (Medline), Cochrane, Science Direct (Embase), Scopus and CRD York Database. of the total of 16 studies identified, 11 studies reported prevalence-based estimates, 2 studies focused on incidence-based data and 3 articles presented both types of Cost data. A large variation concerning Cost components and estimates can be noted. Only three studies estimated indirect Costs. Most of the included studies have shown that the Costs for hospital admission are the most expensive Cost element. Estimates for annual prevalence-based Costs for heart failure patients range from $868 for South Korea to $25,532 for Germany. The lifetime Costs for heart failure patients have been estimated to $126.819 per patient. Our review highlights the considerable and growing economic burden of heart failure on the health care systems. The Cost-of-Illness studies included in this review show large variations in methodology used and the Cost results vary consequently. High quality data from Cost-of-Illness studies with a robust methodology applied can inform policy makers about the major Cost drivers of heart failure and can be used as the basis of further economic evaluations.
-
Cost of Illness in Colorectal Cancer: An International Review
PharmacoEconomics, 2013Co-Authors: Christine Kriza, Martin Emmert, Philip Wahlster, Charlotte Niederländer, Peter Kolominsky-rabasAbstract:Objectives Given the current—and increasing—pressure to limit expenditure on health care provision in many countries, a better understanding of the Cost burden of colorectal cancer is needed. Cost-of-Illness studies and reviews thereof can be a useful tool for analysing and critically evaluating the Cost-related development of colorectal cancer, and they highlight important Cost drivers.
Wladimir Lesyuk - One of the best experts on this subject based on the ideXlab platform.
-
Cost-of-Illness studies in heart failure: a systematic review 2004–2016
BMC cardiovascular disorders, 2018Co-Authors: Wladimir Lesyuk, Christine Kriza, Peter Kolominsky-rabasAbstract:Heart failure is a major and growing medical and economic problem worldwide as 1–2% of the healthcare budget are spent for heart failure. The prevalence of heart failure has increased over the past decades and it is expected that there will be further raise due to the higher proportion of elderly in the western societies. In this context Cost-of-Illness studies can significantly contribute to a better understanding of the drivers and problems which lead to the increasing Costs in heart failure. The aim of this study was to perform a systematic review of published Cost-of-Illness studies related to heart failure to highlight the increasing Cost impact of heart failure. A systematic review was conducted from 2004 to 2016 to identify Cost-of-Illness studies related to heart failure, searching PubMed (Medline), Cochrane, Science Direct (Embase), Scopus and CRD York Database. of the total of 16 studies identified, 11 studies reported prevalence-based estimates, 2 studies focused on incidence-based data and 3 articles presented both types of Cost data. A large variation concerning Cost components and estimates can be noted. Only three studies estimated indirect Costs. Most of the included studies have shown that the Costs for hospital admission are the most expensive Cost element. Estimates for annual prevalence-based Costs for heart failure patients range from $868 for South Korea to $25,532 for Germany. The lifetime Costs for heart failure patients have been estimated to $126.819 per patient. Our review highlights the considerable and growing economic burden of heart failure on the health care systems. The Cost-of-Illness studies included in this review show large variations in methodology used and the Cost results vary consequently. High quality data from Cost-of-Illness studies with a robust methodology applied can inform policy makers about the major Cost drivers of heart failure and can be used as the basis of further economic evaluations.
-
Cost of Illness studies in heart failure a systematic review 2004 2016
BMC Cardiovascular Disorders, 2018Co-Authors: Wladimir Lesyuk, Christine Kriza, P KolominskyrabasAbstract:Heart failure is a major and growing medical and economic problem worldwide as 1–2% of the healthcare budget are spent for heart failure. The prevalence of heart failure has increased over the past decades and it is expected that there will be further raise due to the higher proportion of elderly in the western societies. In this context Cost-of-Illness studies can significantly contribute to a better understanding of the drivers and problems which lead to the increasing Costs in heart failure. The aim of this study was to perform a systematic review of published Cost-of-Illness studies related to heart failure to highlight the increasing Cost impact of heart failure. A systematic review was conducted from 2004 to 2016 to identify Cost-of-Illness studies related to heart failure, searching PubMed (Medline), Cochrane, Science Direct (Embase), Scopus and CRD York Database. of the total of 16 studies identified, 11 studies reported prevalence-based estimates, 2 studies focused on incidence-based data and 3 articles presented both types of Cost data. A large variation concerning Cost components and estimates can be noted. Only three studies estimated indirect Costs. Most of the included studies have shown that the Costs for hospital admission are the most expensive Cost element. Estimates for annual prevalence-based Costs for heart failure patients range from $868 for South Korea to $25,532 for Germany. The lifetime Costs for heart failure patients have been estimated to $126.819 per patient. Our review highlights the considerable and growing economic burden of heart failure on the health care systems. The Cost-of-Illness studies included in this review show large variations in methodology used and the Cost results vary consequently. High quality data from Cost-of-Illness studies with a robust methodology applied can inform policy makers about the major Cost drivers of heart failure and can be used as the basis of further economic evaluations.
